Evaxion Biotech A/S - EVAX Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $42.00
  • Forecasted Upside: 1,029.03%
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$3.72
▲ +0.12 (3.33%)

This chart shows the closing price for EVAX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Evaxion Biotech A/S Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for EVAX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for EVAX

Analyst Price Target is $42.00
▲ +1,029.03% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Evaxion Biotech A/S in the last 3 months. The average price target is $42.00, with a high forecast of $70.00 and a low forecast of $14.00. The average price target represents a 1,029.03% upside from the last price of $3.72.

This chart shows the closing price for EVAX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 3 investment analysts is to moderate buy stock in Evaxion Biotech A/S. This Moderate Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
9/5/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
12/4/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
3/4/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
6/2/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
8/31/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
11/29/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
1/28/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
2/27/2024

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/12/2024HC WainwrightInitiated CoverageBuy$14.00Low
12/21/2023LADENBURG THALM/SH SHReiterated RatingBuy ➝ NeutralLow
3/31/2023Lake Street CapitalLower TargetBuy$180.00 ➝ $70.00Low
11/17/2022OppenheimerLower TargetOutperform$160.00 ➝ $110.00Low
7/18/2022OppenheimerReiterated RatingOutperform$160.00Low
7/30/2021Lake Street CapitalInitiated CoverageBuy$210.00Medium
6/23/2021LADENBURG THALM/SH SHReiterated RatingBuyC$230.00High
3/2/2021OppenheimerInitiated CoverageOutperform$180.00High
3/2/2021LADENBURG THALM/SH SHInitiated CoverageBuyHigh
(Data available from 2/28/2019 forward)

News Sentiment Rating

0.48 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
8/2/2023
  • 2 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
9/1/2023
  • 3 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/1/2023
  • 0 very positive mentions
  • 1 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
10/31/2023
  • 1 very positive mentions
  • 3 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
11/30/2023
  • 3 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
12/30/2023
  • 2 very positive mentions
  • 4 positive mentions
  • 2 negative mentions
  • 2 very negative mentions
1/29/2024
  • 2 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/28/2024

Current Sentiment

  • 2 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Evaxion Biotech A/S logo
Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, a cancer immunotherapy that is in clinical Phase IIb trial for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy that is in Phase 1/2a trial for adjuvant melanoma; and EVX-03, a DNA-based immunotherapy for the treatment of various cancers. Its programs also include EVX-B1, EVX-B2, and EVX-V1, which are vaccines that are in pre-clinical stage for the treatment of bacterial and viral diseases. Evaxion Biotech A/S was incorporated in 2008 and is based in Hørsholm, Denmark.
Read More

Today's Range

Now: $3.72
Low: $3.62
High: $3.79

50 Day Range

MA: $5.97
Low: $3.60
High: $10.65

52 Week Range

Now: $3.72
Low: $3.36
High: $18.50

Volume

13,137 shs

Average Volume

1,031,864 shs

Market Capitalization

$14.10 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Evaxion Biotech A/S?

The following sell-side analysts have issued stock ratings on Evaxion Biotech A/S in the last twelve months: HC Wainwright, LADENBURG THALM/SH SH, and Lake Street Capital.
View the latest analyst ratings for EVAX.

What is the current price target for Evaxion Biotech A/S?

2 Wall Street analysts have set twelve-month price targets for Evaxion Biotech A/S in the last year. Their average twelve-month price target is $42.00, suggesting a possible upside of 1,029.0%. Lake Street Capital has the highest price target set, predicting EVAX will reach $70.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $14.00 for Evaxion Biotech A/S in the next year.
View the latest price targets for EVAX.

What is the current consensus analyst rating for Evaxion Biotech A/S?

Evaxion Biotech A/S currently has 1 hold rating and 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for EVAX.

What other companies compete with Evaxion Biotech A/S?

How do I contact Evaxion Biotech A/S's investor relations team?

Evaxion Biotech A/S's physical mailing address is BREDGADE 34E, COPENHAGEN K G7, 1260. The company's listed phone number is 45-5353-1850 and its investor relations email address is [email protected]. The official website for Evaxion Biotech A/S is www.evaxion-biotech.com. Learn More about contacing Evaxion Biotech A/S investor relations.